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Voltage-dependent anion channelEffective therapies are needed for the treatment of amyotrophic lateral sclerosis (ALS), a fatal type of motor
neuron disease. Morphological, biochemical, molecular genetic, and cell/animal model studies suggest that
mitochondria have potentially diverse roles in neurodegenerative disease mechanisms and neuronal cell
death. In human ALS, abnormalities have been found in mitochondrial structure, mitochondrial respiratory
chain enzymes, and mitochondrial cell death proteins indicative of some non-classical form of programmed
cell death. Mouse models of ALS are beginning to reveal possible principles governing the biology of selective
neuronal vulnerability that implicate mitochondria. This minireview summarizes work on the how
malfunctioning mitochondria might contribute to neuronal death in ALS through the biophysical entity
called the mitochondrial permeability pore (mPTP). The major protein components of the mPTP are enriched
in mouse motor neurons. Early in the course of disease in ALS mice expressing human mutant superoxide
dismutase-1, mitochondria in motor neurons undergo trafﬁcking abnormalities and dramatic remodeling
resulting in the formation of mega-mitochondria and coinciding with increased protein carbonyl formation
and nitration of mPTP components. The genetic deletion of a major mPTP component, cyclophilin D, has
robust effects in ALS mice by delaying disease onset and extending survival. Thus, attention should be
directed to the mPTP as a rational target for the development of drugs designed to treat ALS.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
ALS is a progressive and severely disabling fatal neurological
disease in humans characterized by initial muscle weakness, and
then muscle atrophy, spasticity, and eventual paralysis and death
typicallywithin 3 to 5 years after symptoms begin [1]. The cause of the
spasticity, paralysis and death is progressive degeneration and
elimination of upper motor neurons (MNs) in cerebral cortex and
lower MNs in brainstem and spinal cord [1,2]. Degeneration and loss
of spinal and neocortical interneurons has also been found in human
ALS [3,4]. More than 5000 people in the United States are diagnosed
with ALS each year (ALS Association, www.alsa.org), and, in parts of
the United Kingdom, three people die everyday from some form of
MN disease (www.uk-mnd-professional-network.com). Other than
life support management, no effective treatments exist for ALS [5].
It is still not understood why speciﬁc neuronal populations are
selectively vulnerable in ALS, such as certain somatic MNs and inter-
neurons [3,4]. Themolecular pathogenesis of ALS is understood poorly,
contributing to the lack of appropriate target identiﬁcation andrtment of Pathology, 558 Ross
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ll rights reserved.effective mechanism-based therapies to treat this disease. Two
forms of ALS exist: idiopathic (sporadic) and heritable (familial). The
majority of ALS cases are sporadic with few known genetic contribu-
tions, except for missense mutations in TAR-DNA binding protein [6].
Aging is a strong risk factor for ALS because the average age of onset is
55 (ALS Association, www.alsa.org). Familial forms of ALS (fALS) have
autosomal dominant or autosomal recessive inheritance patterns and
make up ~10% or less of all ALS cases. ALS-linked mutations occur in
the genes encoding SOD1 (ALS1), Alsin (ALS2), senataxin (ALS4),
vesicle associated membrane protein (VAMP/synaptobrevin)-associ-
atedprotein B (ALS8), dynactin, TAR-DNAbindingprotein, and fused in
sarcoma (FUS, ALS6) [7,8].
Mitochondrial perturbations have been known for a long time to
participate in the mechanisms of neuropathology, particularly
disorders involving acute interruptions in O2 and substrate delivery
to the brain and bioenergetic failure as seen in tissue ischemia [9,10].
An exciting new understanding of mitochondrial biology has emerged
over the past decade that is likely to be very relevant to age-related
neurodegenerative disorders [7]. Mitochondria are multi-functional
organelles [10]. In addition to their critical role in the production of
ATP through the electron transport chain (Fig. 1), these organelles
function in intracellular Ca2+ homeostasis, steroid, heme and iron-
sulfur cluster synthesis, and programmed cell death [10,11]. They are
also sites of formation of reactive oxygen species (ROS), including
Fig. 1. Mitochrondrial regulation of cell life and death in schematic representation. The respiratory chain proteins (complex I-IV) establish an electrochemical gradient across the
inner mitochondrial membrane (IMM) by extruding protons out of the matrix into the intermembrane space, thereby creating an energy gradient that drives the production on ATP
by complex V (lower left). Superoxide (O2•-) is produced as a by-product in the process of electron transport and is converted to hydrogen peroxide (H2O2) by MnSOD (or CuZnSOD).
In pathological settings that can trigger cell aging and death, H2O2 can be converted to hydroxyl radical (OH), or hydroxyl-like intermediates, andmitochondrial nitric oxide synthase
(NOS) can produce nitric oxide (NO) that can combine with O2•- to form peroxynitrite (ONOO-). CuZnSOD can use ONOO- to catalyze the nitration of mitochondrial protein tyrosine
residues (bottom center) such as cyclophilin D (CyPD) and the adenine nucleotide translocator (ANT) [78]. Bcl-2 family members regulate apoptosis by modulating the release of
cytochrome c frommitochondria into the cytosol. Two models can account for this process (the Bax/Bak channel model and the mitochondrial apoptosis-induced channel or MAC).
In the Bax/Bak1 channel model (left), Bax (Bcl-2-associated X protein) is a pro-apoptotic protein found mostly in the cytosol in healthy mammalian cells but, after speciﬁc cell death
inducing stumuli, Bax undergoes a conformation shift and translocates to the outer mitochondrial membrane (OMM) where it inserts [55,56]. Bak1 (Bcl-2-antagonist/killer 1) is a
similar pro-apoptotic protein localized mostly to the mitochondrial outer membrane. Bax/Bak1 monomers physically interact and form oligomeric or heteromeric channels that are
permeable to cytochrome c. The formation of these channels is blocked by Bcl-2 and Bcl-xL at multiple sites. BH3-only members (Bad, Bid, Noxa, Puma) are pro-apoptotic and can
modulate the conformation of Bax/Bak1 to sensitize this channel, possibly by exposing its membrane insertion domain (not shown). The MAC could be a channel similar to the Bax/
Bak1 channel, but it might also have additional components. Release cytochrome c participates in the formation of the apoptosome in the cytosol that drives the activation of
caspase-3 in motor neurons (see Fig. 2). Second mitochondria-derived activator of caspases (Smac)/ direct IAP-binding protein with low pI (DIABLO) are released into the cytosol to
inactivate the anti-apoptotic actions of inhibitor of apoptosis proteins that inhibit caspases. The DNases AIF and EndoG are released and translocate to the nucleus to stimulate DNA
fragmentation. Another model (right) for mitochondrial directed cell death involves the permeability transition pore (PTP). The PPT is a transmembrane channel formed by the
interaction of the ANT and the voltage-dependent anion channel (VDAC) at contact sites between the IMM and the OMM [114–120]. CyPD, located in the matrix, can regulate the
opening of the PTP by interacting with the ANT. Opening of the PTP induces matrix swelling and OMM rupture leading to release of cytochrome c and other apoptogenic proteins
(AIF, EndoG). Certain Bcl-2 family members can modulate the activity of the PTP.
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or its intermediates [10], and reactive nitrogen species such as nitric
oxide (•NO) [10]. Thus, mitochondria have functions and properties
that might confer an intrinsic susceptibility of subsets of long-lived
post-mitotic cells such as neurons to aging and stress. In this regard
varying degrees of mitochondrial dysfunction and aberrant mito-
chondrial maintenance and repair could be critical determinants in
the regulation of disease and neuronal cell death ranging from
necrosis and apoptosis to autophagy [5,12–14].
2. Mitochondrial abnormalities in human ALS
2.1. Evidence for mitochondrial abnormalities in human ALS
pathogenesis lacks deﬁnite causal relationships
Mitochondrial dysfunction has been implicated in the pathogen-
esis of ALS in humans. Electron microscopy studies have shown
mitochondrial morphology abnormalities in skeletal muscle, liver,
spinal MNs and cortical upper MN regions of ALS patients [15,16]. A
mutation in cytochrome c oxidase subunit I was found in a patientwith a MN disease phenotype [17]. Another patient with MN disease
had a mutation in a mitochondrial tRNA gene [18]. One type of
mitochondrial DNA (mtDNA) mutation, called the common mtDNA
deletion (mtDNA4977), is found non-uniformly within different
human brain areas; the highest levels are detected in the striatum
and substantia nigra [19,20]. However, no signiﬁcant accumulation of
the 5 kb common deletion in mtDNA has been found by single-cell
analysis of MNs from sporadic ALS cases [21]. Some ALS patients with
defects in mitochondrial oxidative phosphorylation in skeletal muscle
have a novel SOD1 mutation [22].
2.2. Intracellular Ca2+ abnormalities and excitotoxicity in human ALS
pathogenesis: links to mitochondrial dysfunction and oxidative stress
Mitochondria function in the regulation of intracellular Ca2+ levels
[11,23]. Regarding ALS, skeletal muscle biopsies of patients with
sporadic disease show ultrastructural changes indicative of elevated
Ca2+ in MN terminals, with somemitochondria showing an augment-
ed Ca2+ signal [24]. Utilizing speciﬁc transport systems mitochondria
can move Ca2+ from the cytosol into the matrix by the Ca2+ uniporter
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ically through the mitochondrial permeability transition pore (mPTP)
[25]. Under conditions of elevated cytoplasmic Ca2+, whenever the
local free Ca2+ concentration rises above a set-point of ~0.5 μM, mito-
chondria avidly accumulate Ca2+ to a ﬁxed capacity [11]. The electrical
gradient across the mitochondrial inner membrane, the ΔΨm,
established by electron transport chain activity (Fig. 1), provides the
driving force for the accumulation of Ca2+ into the mitochondrial
matrix [23]. Cytosolic Ca2+ concentrations above set-point levels are
believed to be achieved during tetanic stimulation and by activation of
glutamate receptors on the plasma membrane [11]. In settings of the
pathological process called excitotoxicity, resulting from excessive
overstimulation of glutamate receptors [26], Ca2+ overload in neurons
is signiﬁcant and cause cell death [27]. When mitochondria become
overloaded with Ca2+, they undergo mitochondrial permeability
transition (see below) resulting in osmotic swelling and rupture of
the outer mitochondrial membrane (Fig. 1). Interestingly, mitochon-
dria within synapses appear to be more susceptible than non-synaptic
mitochondria to Ca2+ overload [28].
Exitotoxicity has been implicated in the pathogenesis of ALS for a
long time [29] and is another possible mechanism by which MNs can
be damaged in ALS [27]. Sporadic ALS patients have reduced levels of
synaptosomal high-afﬁnity glutamate uptake [29] and astroglial
glutamate transporter EAAT2 (excitatory amino acid transporter 2 or
GLT1) in motor cortex and spinal cord [30]. Reductions in levels of
activity of EAAT2 in spinal cord could increase the extracellular
concentrations of glutamate at synapses on MNs. MNs are sensitive to
glutamate excitotoxicity because they have a lowproportion of GluR2-
edited or under-edited AMPA subtype glutamate receptor on their
surfaces, predisposing MNs to risk of excess Ca2+ entry and
mitochondrial perturbations [31,32]. Excess glutamate receptor
activation in neurons can cause increased intracellular Ca2+, mito-
chondrial ROS production, bioenergetic failure, and mitochondrial
trafﬁcking abnormalities [33]. Ca2+-induced generation of ROS in
brain mitochondria is mediated bymitochondrial permeability transi-
tion [34]. MNs are particularly affected by inhibition of mitochondrial
metabolismwhich causes elevated cytosolic Ca2+ levels and increased
excitability [35].
Mitochondria generate endogenous ROS as by-products of oxida-
tive phosphorylation (Fig. 1) [36]. Because many mitochondrial
proteins possess iron-sulfur clusters for oxidation-reduction reactions
and because mtDNA lacks protective histones, these macromolecules
are particularly vulnerable to ROS attack. Electrons in the electron
carriers, such as the unpaired electron of ubisemiquinone bound to
coenzyme Q binding sites of complexes I, II, and III, can be donated
directly to O2 to generate O2•- [36]. O2•- does not easily pass through
biological membranes and thus must be inactivated in compartments
where it is generated [37]. The mitochondrial matrix enzyme
manganese superoxide dismutase (MnSOD or SOD2) or copper/zinc
SOD (Cu/ZnSOD or SOD1) in the mitochondrial intermembrane space
and cytosol convert O2•- to hydrogen peroxide (H2O2) in the reaction
O2•-+O2•-+2H+→H2O2+O2 (Fig. 1) [37]. H2O2 is more stable than O2•-
and can diffuse from mitochondria and into the cytosol and nucleus.
H2O2 is detoxiﬁed by glutathione peroxidase in mitochondria and in
the cytosol and by catalase in peroxisomes. In the presence of reduced
transitional metals (Fe2+), H2O2 is catalyzed to •OH [38]. O2•- can also
react with •NO to form the potent nucleophile and oxidant and
nitrating agent peroxynitrite (ONOO-) (Fig. 1) [39]. ONOO- or products
of ONOO- can damage proteins by nitration [39]. ONOO- is genotoxic
directly to neurons by causing single- and double-strand breaks in
DNA [40]. NO can be produced in mitochondria [41] and has direct
effects in mitochondria. NO at nanomolar concentrations can inhibit
rapidly and reversibly respiration [42].
Markers of oxidative stress and ROS damage are elevated in ALS
tissues [43]. In human sporadic ALS, protein carbonyls are elevated in
motor cortex [44]. Tyrosine nitration is elevated in humanALS nervoustissues [45–47]. Studies of respiratory chain enzyme activities are
discrepant. Studies have reported increases in complex I, II, and III
activities in vulnerable and non-vulnerable brain regions in patients
with mutant SOD1-fALS [48], but other studies have found decreased
complex IV activity in spinal cord ventral horn [49] and skeletalmuscle
[50] of sporadic ALS cases. In sporadic ALS skeletal muscle, reductions
in activity of respiratory chain complexes with subunits encoded by
themitochondrial genome are associatedwith decreased neuronal NO
synthase levels [51]. Alterations in skeletal muscle mitochondria are
progressive [52] and could be intrinsic to skeletal muscle [53] and not
due merely to neurogenic atrophy as assumed commonly.
3. Human ALS and mitochondrial orchestrated programmed cell
death (PCD) involving p53
3.1. Degeneration of motor neurons in human ALS has features of PCD
PCD is physiologically regulated cell death [12]. Apoptosis, a formof
PCD, is a structurally and biochemically organized, transcriptionally-
dependent or –independent, formof cell death. The basicmachinery of
apoptosis is conserved in yeast, hydra, nematode, fruit ﬂy, zebraﬁsh,
mouse, and human [54]. Mitochondria regulate cell death processes
(Figs. 1, 2). A variety of mitochondrial proteins function in apoptosis
(Table 1) including Bcl-2 family members, cytochrome c, apoptosis
inducing factor (AIF), endonuclease G, secondmitochondrial activator
of caspases (Smac/DIABLO), and Omi/high-temperature requirement
protein A2 (HtrA2) inhibitor of the inhibitors of apoptosis proteins
(Fig. 1) [55–57]. Other proteins (e.g., humanin, Ku70, 14-3-3 proteins)
that are notmitochondrial canmodulatemitochondrially translocated
cell death proteins by binding and sequestration. For example, Ku70
blocks the translocation of Bax to mitochondria to restrain cell death
[58].
PCD appears to contribute to the selective degeneration of MNs in
human sporadic ALS and fALS, albeit seemingly as a non-classical form
differing from apoptosis (Fig. 2) [59]. MNs appear to pass through
sequential stages of chromatolysis (suggestive of initial axonal
injury), somatodendritic attrition without extensive cytoplasmic
vacuolation, and then nuclear DNA fragmentation, nuclear condensa-
tion, and cell death (Fig. 3) [59]. MNs in individuals dying from
sporadic ALS and fALS show the same patterns of degeneration [59].
This cell death in human MNs is deﬁned clearly by genomic DNA
fragmentation (determined by DNA agarose gel electrophoresis and in
situ DNA nick-end labeling) and cell loss and is associated with
accumulation of mitochondria, cytochrome c, and cleaved caspase-3
(Figs. 2, 3) [60]. However, the morphology of this cell death is distinct
from classical apoptosis, despite the nuclear condensation [12,61].
Nevertheless, Bax and Bak1 protein levels are increased in mitochon-
dria-enriched fractions of selectively vulnerable motor regions (spinal
cord anterior horn and motor cortex gray matter), but not in regions
unaffected by the disease (somatosensory cortex gray matter). In
marked contrast, Bcl-2 protein is severely depleted in mitochondria-
enriched fractions of affected regions and is sequestered in the cytosol
(Fig. 2) [59]. Although these western blot observations lacked direct
speciﬁcity for MN events [59], subsequent immunohistochemistry
(Figs. 2, 3) [60] and laser capture microdissection of MNs combined
with mass spectroscopy-protein proﬁling have conﬁrmed the pres-
ence of intact active caspase-3 in human ALS MNs [62].
3.2. Degeneration of motor neurons in human ALS is associated with
p53 activation
Neuronal apoptosis can be driven by the tumor suppressor p53
[63]. This cell death can be transcriptionally-dependent and tran-
scriptionally-independent [63]. p53 can mediate mitochondrial
permeabilization through direct physical interactionwith Bcl-2 family
members [64]. p53 is activated in MNs in human ALS [65]. p53 levels
Fig. 2. PCDmechanisms regulate the degeneration of motor neurons in human amyotrophic lateral sclerosis. The levels of multidomain Bcl-2 family members are aberrant in isolated
mitochondria from human amyotrohpic lateral sclerosis (ALS) brain and spinal cord [59]. Bcl-2 is depleted from mitochondria by unknown mechanisms (top schematic drawing).
Bax and Bak levels are elevated in mitochondria (top schematic drawing). These changes would favor the release of cytochrome c from mitochondria and the accumulation of
cytochrome c in the cytoplasm of motor neurons (A). Human ALS motor neurons are rich in mitochondria, as identiﬁed by cytochrome c oxidase subunit I (B, brown labeling) and
many are positive for cleaved capsase-3 (B, blue-green labeling). These observations are consistent with an accumulation of somatodendritic mitochondria and apoptosome-
mediated activation of caspase-3 in ALS motor neurons. These changes appear to be occurring slowly in subsets of motor neurons and could lead to cell death that is a variant
phenotype of apoptosis (see Fig. 3). In human ALSmotor neurons, it is not known yet if alterations occur in the components of the mPTP (top schematic drawing), such as cyclophilin
D (CypD), adenine nucleotide translocator (ANT), and voltage-dependent anion channel (VDAC). Scale bars=6 µm (A); 3 µm (B).
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Table 1
Some Mitochondrial Associated Proteins That Function in Cell Death.
Protein Function
Bcl-2⁎ Antiapoptotic, blocks Bax/Bak channel formation
Bcl-XL Antiapoptotic, blocks Bax/Bak channel formation
Bax⁎ Proapoptotic, forms pores for cytochrome release
Bak⁎ Proapoptotic, forms pores for cytochrome release
Bad Proapoptotic, decoy for Bcl-2/Bcl-XL
promoting Bax/Bak pore formation
Bid Proapoptotic, decoy for Bcl-2/Bcl-XL
promoting Bax/Bak pore formation
Noxa Proapoptotic, decoy for Bcl-2/Bcl-XL
promoting Bax/Bak pore formation
Puma Proapoptotic, decoy for Bcl-2/Bcl-XL
promoting Bax/Bak pore formation
p53⁎ Antagonizes activity of Bcl-2/Bcl-XL,
promotes Bax/Bak oligomerization
Cytochrome c Activator of apoptosome
Smac/DIABLO IAP inhibitor
AIF Antioxidant ﬂavoprotein/released from
mitochondria to promote nuclear DNA
fragmentation
Endonuclease G Released from mitochondria to promote
nuclear DNA fragmentation
HtrA2/Omi IAP inhibitor
VDAC mPTP component in outer mitochondrial membrane
ANT+ mPTP component in inner mitochondrial membrane
Cyclophilin D+ mPTP component in mitochondrial matrix
TSPO (peripheral
benzodiazepine receptor)
Modulator of mPTP
Hexokinase Modulator of VDAC
⁎ Known to be changed in human ALS [59,65].
+ Oxidatively modiﬁed in mouse ALS [78].
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lates speciﬁcally in ALS MN [65]. This p53 is active functionally
because it is phosphorylated at serine392 and has increased DNA
binding activity [61,65].
These data support the concept of an aberrant re-emergence of a
PCD mechanism, involving p53 activation and cytosol-to-mitochon-
dria redistributions of cell death proteins, participating in the patho-
genesis of MN degeneration in human ALS [59,95]. The morphological
and biochemical changes seen in humanALS aremodeled robustly and
faithfully at structural and molecular levels in axotomy models of MN
degeneration in adult mouse [66] but not in the current commonly
used human mutant SOD1 transgenic mouse models (Fig. 3) [60].
4. Mitochondrial pathobiology in cell and mouse models of ALS
A common mutation in human SOD1 that is linked to fALS is the
substitution of glycine by alanine at position 93 (G93A) [67,68]. SOD1
is a metalloenzyme of 153 amino acids (~16 kDa) that binds one
copper ion and one zinc ion per subunit [37]. This enzyme, functioning
as a ~32 kDa non-covalently linked homodimer, is responsible for the
detoxiﬁcation and maintenance of intracellular O2•- concentration in
the low femtomolar range by catalyzing its dismutation [37,69]. SOD1
is ubiquitous (intracellular SOD concentrations are typically ~10-
40 μM) in most tissues and possibly greater in neurons [70].
4.1. Evidence for mitochondrial abnormalities in cell models of ALS
Data from cell culture studies argue strongly for mitochondria
dysfunction, possibly MN selective, in the presence of mSOD1 [67,71].
Expression of several human SOD1 mutants increases mitochondrial
O2•- levels and causes toxicity in primary MNs [72], neuroblastoma
cells [73], and NSC-34 cells (a hybrid cell line with some MN-like
characteristics, produced by fusion of MN-enriched embryonic mouse
spinal cord cells with mouse neuroblastoma cells) [74,75]. These
responses can be attenuated by over-expression of MnSOD [73]. ALS-
mSOD1 variants, compared to wild-type SOD1, associate more withmitochondria in NSC-34 cells and appear to form cross-linked
oligomers that shift the mitochondrial GSH/GSSH ratio toward
oxidation [71].
4.2. Most evidence for mitochondrial abnormalities in mouse ALS
pathogenesis lacks deﬁnite causal relationships
Gurney et al were the ﬁrst to develop transgenic (tg) mice that
express the G93A mutant form of human SOD1 [76,77]. Now, these
mice are used widely as an animal model of ALS [5,60,67,68]. Human
mutant SOD1 (mSOD1) is expressed ubiquitously in these mice by its
endogenous promoter in a tissue/cell non-selective pattern against a
background of normal mouse SOD1 [76]. Effects of this humanmutant
gene in mice are profound. Hemizygous tg mice expressing high copy
number of the G93A variant of mSOD1 become completely paralyzed
and die at ~16-18 weeks of age [76]. G93A-mSOD1mice with reduced
transgene copy number have a much slower disease progression and
die at ~8-9 months of age [76,78]. Spinal MNs and interneurons in
mice expressing G93Ahigh-mSOD1 undergo prominent degeneration;
about 70% of lumbar MNs are eliminated by end-stage disease [79,80].
More work is needed on the cell death and its mechanisms in
G93Alow-expressing mice. Subsets of spinal interneurons are lost
before MNs G93Ahigh-mSOD1 [79], some of which are the glycinergic
Renshaw cells [80]. Unlike the degeneration of MN in human ALS,
MNs in these mice do not degenerate with a morphology resembling
any form of apoptosis (Fig. 3) [60,79,81]. The MNs degeneration seen
in G93Ahigh-mSOD1 mice more closely resembles a prolonged
necrotic-like cell death process (Fig. 3) [12] involving early-occurring
mitochondrial damage, cellular swelling, and dissolution [60,78–80].
Biochemically, the death of MNs is characterized by somal and
mitochondrial swelling and formation of DNA single-strand breaks
prior to double-strand breaks occurring in nuclear DNA and
mitochondrial DNA [79]. The MN death is independent of activation
of caspases-1 and 3, and also appears to be independent of capsase-
8 and apoptosis-inducing factor activation within MNs [79]. Indeed,
caspase-dependent and p53-mediated apoptosis mechanisms might
be blocked actively in G93Ahigh-mSOD1 mouse MNs, possibly by
upregulation of inhibitors of apoptosis and changes nuclear import of
proteins [79].
Mitochondrial pathology has been implicated in the mechanisms
of human and mouse ALS [7], but most evidence is circumstantial. In
different mSOD1 mouse models of ALS, mitochondria in spinal cord
neurons exhibit structural pathology [79,82–86] and some of the
mitochondrial degeneration occurs very early in the course of the
disease [79,81]. Mitochondrial microvacuolar damage in MNs
emerges by 4 weeks of age in G93Amice with high expression [79,81].
It has been argued that mitochondrial damage in G93Ahigh-mSOD1
mice is related to supra-normal levels of SOD1 and might not be
related causally to the disease process because transgenic mice
expressing high levels of human wildtype SOD1 show some
mitochondrial pathology [87], but mitochondrial abnormalities have
been found histologically also in G93Alow-mSOD1mice [88](Martin LJ
et al, unpublished observations). Thus, mitochondria could be primary
sites of human SOD1 toxicity in transgenic mice irrespective of
transgene copy number and expression level of human SOD1, but
direct, unequivocal causal relationships have been lacking.
Human SOD1 mutant proteins appear to gain a toxic property
or function, rather than having diminished O2- scavenging activity
[89–91], and wild-type SOD1 can gain toxic properties through
oxidative modiﬁcation [92,93]. A gain in aberrant oxidative chemistry
could contribute to the mechanisms of mitochondriopathy in
G93Ahigh mice [39,94]. G93A-mSOD1 has enhanced free radical-
generating capacity compared to wild-type enzyme [91] and can
catalyze protein oxidation by hydroxyl-like intermediates and
carbonate radical [95]. G93Ahigh mice have increased protein carbonyl
formation in total spinal cord tissue extracts at pre-symptomatic
Fig. 3. Comparison of motor neuron death phenotypes in human and transgenic mouse amyotrohpic lateral sclerosis. The degeneration of spinal motor neuron (MNs) in human fALS
and in G93Ahigh mSOD1 mouse is very different. A-C. Normal anterior horn MNs in human spinal cord are large polygonal multipolar cells as seen with cresyl violet staining (A). In
human fALS, the degeneration is typiﬁed by shrinkage and progressive condensation of the cytoplasm and nucleus (B,C, * identiﬁes the nucleus). The cell in (c) is identiﬁed as a dying
MN based the large nucleolus and residual large Nissl bodies. D. These shrunken human MNs usually have large-scale genomic fragmentation of DNA as detected by terminal
transferase-mediated biotin-dUTP nick-end labeling (TUNEL). Brown labeling in nucleus (asterisk) reveals the presence of DNA-double strand breaks. E. DegeneratingMNs in human
ALS are always immunopositive for cleaved caspase-3 (black-dark green labeling) in the somatodendritic attrition stage and accumulate around the nucleus (asterisk) discrete
mitochondria (brown-orange labeling, detected with antibody to cytochrome c oxidase subunit I) exhibiting little light microscopic evidence for swelling. F. Human wild-type SOD1
transgenic mice have mostly normal appearing spinal MNs as seen with cresyl violet staining. G-I. In G93Ahigh mSOD1mice (G1 line), the degeneration is typiﬁed by progressive
cytoplasmic vacuolization and cellular swelling and dissolution (* identiﬁes the nucleus) that begins at about 4-6 weeks of age develops severely from 8 to 16 weeks of age. This
degeneration more closely resembles a form of slowly occurring necrosis. Neither the cytoplasm nor the nucleus undergoes condensation during their degeneration. Scale bars: A
(same for B,C)=8 μm; D (same for E)=12 μm; F (same for G-I) = 10 μm.
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enriched fractions of spinal cord is a robust signature of incipient
disease [78]. A mass spectroscopy study of G93Ahigh mice identiﬁed
proteins in total spinal cord tissue extracts with greater than baseline
carbonyl modiﬁcation, including SOD1, translationally controlled
tumor protein, and ubiquitin carboxyl-terminal hydrolase-L1 [97].
Nitrated and aggregated cytochrome c oxidase subunit-I and α-
synuclein accumulate in G93Ahigh mouse spinal cord [79]. Nitrated
MnSOD accumulates also in G93Ahigh mouse spinal cord [79]. Toxicproperties of mSOD1 could also be mediated through protein binding
or aggregation. Wild-type SOD1 and human mSOD1 associate with
mitochondria [85,98]. Human SOD1 mutants associate with spinal
cord mitochondria in mSOD1 mice and can bind Bcl-2 [99,100], thus
potentially being decoys or dominant negative regulators of cell
survival molecules (Fig. 2), but it is not known if this process is
occurring speciﬁcally in mouse MNs. Bcl-2 is depleted from mito-
chondria isolated frommicropunches of humanALS anterior horn gray
matter and accumulates in the cytosol (Fig. 2) [59]. Binding of mSOD1
192 L.J. Martin / Biochimica et Biophysica Acta 1802 (2010) 186–197(and perhaps its low-mobility species) to mitochondria has been
reported to be spinal cord selective and age-dependent [101], but this
work lacks cellular resolution. A recent biochemical in vitro study has
shown that endogenous SOD1 in the mitochondrial intermembrane
space controls cytochrome c-catalyzed peroxidation and that G93A-
mSOD1mediates greater ROS production in the intermembrane space
compared to wild-type SOD1 [102]. Human SOD1 mutants can also
shift mitochondrial redox potential when expressed in cultured cells
[71]. Nevertheless, the direct links between the physicochemical
changes in mSOD1 and wild-type SOD1 and the mitochondrial
functional and structural changes associated with ALS and MN
degeneration remain uncertain.
EM studies have shown that the outer mitochondrial membrane
(OMM) remains relatively intact to permit formation of mega-
mitochondria in MNs cell bodies in G93Ahigh mice [78,79]. Moreover,
early in the disease of these mice, mitochondria in dendrites in spinal
cord ventral horn undergo extensive cristae and matrix remodeling,
while few mitochondria in MN cell bodies show major structural
changes [78]. Another interpretation of ultrastructural ﬁndings is that
the mSOD1 causes mitochondrial degeneration by inducing OMM
extension and leakage and intermembrane space expansion [86].
Mechanisms for this damage could be related to mSOD1 gaining
access to the mitochondrial intermembrane space [83,102] and the
matrix [103] and inducing disturbances in oxidative phosphorylation
[104] and antioxidant activity. This mitochondrial conformation seen
by EM might favor the formation of the mPTP (Fig. 1); indeed, we
found evidence for increased contact sites between the OMM and
inner mitochondrial membrane (IMM) in dendritic mitochondria in
G93Ahigh mice [78]. Another feature of MNs of young G93Ahigh mice
before symptoms is apparent ﬁssion of ultrastructurally normal
mitochondria in cell bodies and fragmentation of abnormal mito-
chondria [78]. It is not clear if the cristae and matrix remodeling and
the apparent fragmentation and ﬁssion mitochondria are related or
independent events and if these abnormalities interfere with mito-
chondrial trafﬁcking; nevertheless, morphological observations en-
force the idea that mitochondria are critical to the pathobiology of
mSOD1 toxicity to MNs in G93Ahigh mice.
The possibility of changes in mitochondrial trafﬁcking in MNs of
mSOD1 mice is mostly unexplored. Some data support the novel idea
that mitochondria might act as messengers from distal regions of MNs
in mSOD1 mice [7]. G93Ahigh-mSOD1 mouse MNs accumulate mito-
chondria from the axon terminals and generate higher levels of O2•-,
•NO, and ONOO- thanMNs in transgenic mice expressing humanwild-
type SOD1 [79]. This mitochondrial accumulation occurs at a time
when MN cell body volume is increasing, suggestive of ongoing
problemswith ATP production or plasmamembraneNa,K ATPase [79].
G93A-mSOD1 perturbs anterograde axonal transport of mitochondria
in cultured primary embryonic MNs [105] making it possible that
retrogradely transported mitochondria with toxic properties from the
neuromuscular junction fail to be returned to distal processes [7,79].
Mitochondria with enhanced toxic potential from distal axons and
terminals could therefore have a “Trojan horse” role in triggering
degeneration of MNs in ALS via retrograde transport from diseased
skeletal muscle.
MNs in G93Ahigh-mSOD1 mice also accumulate higher levels of
intracellular Ca2+ thanMNs in transgenic humanwild-type SOD1mice
[79]. The intracellular Ca2+ signal in MNs is very compartmental and
mitochondrial-like in its appearance [79,106]. Abnormal elevations
intracellular Ca2+ inG93Ahigh-mSOD1mouseMNshave been seen also
by different Ca2+ detection methods [107,108]. Brain and spinal cord
mitochondria in G93A mice handle Ca2+ abnormally and have im-
paired Ca2+ uptake capacity [109], but this work lacks cellular resolu-
tion. However, recent elegant work using a mouse neuromuscular
junction preparation has revealed that, speciﬁcally within MN ter-
minals, mitochondrial Ca2+ accumulation is accompanied by greater
IMM depolarization in human mutant SOD1 transgenic mice [110].NO signaling mechanisms in mitochondria of ALS mice have also
been implicated in the pathogenesis (Fig. 1). MNs seem to be unique
regarding NO production because the express constitutively low
levels of inducible NO synthase (iNOS) [106]. G93Ahigh-mSOD1mouse
MNs accumulate nicotinamide adenine dinucleotide phosphate
diaphorase and iNOS-like immunoreactivity [79]. iNOS is also up-
regulated aberrantly in human sporadic ALS MNs [111]. iNOS gene
deletion extends signiﬁcantly the lifespan of G93Ahigh-mSOD1 mice
[79]. Thus, mitochondrial oxidative stress, Ca2+ dysregulation, iNOS
activation, protein nitration, and protein aggregation (not necessarily
SOD1 though) are all likely intrinsic, cell automonous mechanisms in
the process of MN degeneration caused by mSOD1 in mice [79]. The
mechanistic basis for the differences between human ALS and mSOD1
mice, regarding cell death phenotype (Fig. 3), is not yet clear but could
be related to the supra-normal expression of toxic mSOD1 or to
fundamental differences in cell death mechanisms [60] or the tissue
inﬂammatory milieu (Martin LJ, unpublished observations) that drive
MNs in mSOD1 transgenic mice to necrotic-like death along the
apoptosis-necrosis cell death continuum [12,13,106]. Another con-
tributing factor for this difference between human and mouse MNs is
that mitochondria are functionally diverse and have species-speciﬁc
activities and molecular compositions, including the makeup of the
mitochondrial permeability transition pore [112]. These possiblities
allow for skepticism regarding the suitability of existing transgenic
mSOD1 mouse lines to model human ALS.
5. The mitochondrial permeability transition pore contributes to
the causal mechanisms of ALS in mice
Despite the implication of toxic effects of mSOD1 on mitochondria
in mouse ALS, cause-effect relationships between abnormal function-
ing of mitochondria and initiation and progression of disease have
been uncertain. These relationships need to be known because this
knowledge could provide a rationale for new mechanism-based
treatments for ALS. One venue of investigation for mitochondrial
damage causality is the mPTP and its possible involvement in ALS.
5.1. The mPTP: Deﬁnition and molecular composition
Mitochondrial permeability transition is a mitochondrial state in
which the proton-motive force is disrupted reversibly or irreversibly
[25,76,113–117]. Conditions of mitochondrial Ca2+ overload, exces-
sive oxidative stress, and decreased electrochemical gradient (ΔP),
ADP, and ATP can favor mitochondrial permeability transition. This
alter state of mitochondria involves the mPTP that functions as a
voltage, thiol, and Ca2+ sensor [25,76,113–117]. The mPTP is believed
to be a poly-protein transmembrane channel formed at the contact
sites between the IMM and the OMM. The collective components of
the mPTP are still controversial, but the voltage-gated anion channel
(VDAC, or porin) in the OMM, the adenine nucleotide translocator
(ANT, or solute carrier family 25) in the IMM, and cyclophilin D
(CyPD) in thematrix are believed to be the core components (Table 1)
[114–116]. Other components ormodulators of themPTP appear to be
hexokinase, creatine kinase, translocator protein 18 kDa (TSPO, or
peripheral benzodiazepine receptor), and Bcl-2 family members
(Table 1) [113–117].
The VDAC family in human andmouse consists of three proteins of
~31 kDa (VDAC1-3) encoded by three different genes [118]. VDACs
are the major transport proteins in the OMM, functioning in ATP
rationing, Ca2+ homeostasis, oxidative stress response, and apoptosis
[118]. Monomeric VDAC serves as the functional channel, although
oligomerization of VDAC into dimers and tetramers can occur and
might function in cell death [118]. The VDAC adopts an open confor-
mation at low or zeromembrane potentials and a closed conformation
at potentials above 30-40 mV making the OMM permeable to
most small hydrophilic molecules up to 1.3 kDa for free exchange of
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opening or closing as an important regulator of cell death are based
on in vitro conditions, while limited in vivo evidence is available
[120]. VDAC1 binds Bak1, hexokinase, gelsolin, and ANT1/ANT2;
VDAC2 binds Bak1, hexokinase, cytochrome c, glycerol kinase, and
ANT1/ANT2; VDAC3 binds glycerol kinase, CyPD, and ANT1-3 [118]. In
human tissues, VDAC1 and VDAC2 isoforms are expressed more
abundantly than VDAC3; highest levels are found in kidney, heart,
skeletal muscle, and brain [121]. The effects of selective knockout of
VDAC isoforms are not equivalent, implying different functions. Mice
deﬁcient in either VDAC1 or VDAC3 are viable [122–124], but VDAC2
deﬁciency causes embryonic lethality [125]. Lack of both VDAC1 and
VDAC3 causes growth retardation [124]. VDAC null mouse tissues
exhibit deﬁcits in mitochondrial respiration and abnormalities in
mitochondrial ultrastructure [122]. Mitochondria without VDAC1
have an intact mitochondrial permeability transition response
[126,127]. VDAC2 deletion, but not lack of the more abundant
VDAC1, results in enhanced activation the mitochondrial apoptosis
pathway and enforced activation of Bak at mitochondria [125], con-
sistent with the idea that VDAC2 is a key inhibitor of Bak-mediated
apoptosis [124]. However, other data show that cells lacking individual
VDACs or combinations of VDACs have normal death responses to Bax
and Bid [127]. New work in yeast has revealed that SOD1 is necessary
for proper functioning of VDAC; speciﬁcally, SOD1 regulates VDAC
channel activity and protein levels in mitochondria [128].
The mitochondrial ANT family in human consists of 3 members
(ANT1-3, or solute carrier family 25, members 4, 5, and 6) encoded by
three different genes, but in mouse only two isoforms of the ANT are
present [128]. The proteins are ~33 kDa and function as homodimers
[128]. They are multi-pass membrane proteins, with odd-numbered
transmembrane helices having kinks because of proline residues,
whichmediate exchangeof cytosolic ADP formitochondrial ATP across
the inner membrane utilizing the electrochemical gradient [129].
ANT1 binds VDAC1, CyPD, Bax, twinkle (ataxin-8), and cyclophilin-40;
ANT2 binds VDAC1-3 and cyclophilin-40; ANT3 binds VDAC1, steroid
sulfatase, and translocase of innermitochondrial membrane 13 and 23
[128]. The ANT isoforms are expressed differentially in tissue- and
species-speciﬁc patterns [130]. ANT1 is expressed highly in human
and mouse heart and skeletal muscle, and human brain has low ANT1
mRNA but high ANT3mRNA, while mouse brain has high ANT1mRNA
[130]. ANT2 mRNA is very low or not expressed in most adult human
and mouse tissues, with kidney having some expression [130]. In
tissuemitochondriawheremore than one ANT is found, it is ANT1 that
binds preferentially to CyPD to form themPTP at contact sites between
the inner and outer mitochondrial membranes [131]. It has been
proposed that, in the presence of highmitochondrial Ca2+, the binding
of CyPD to proline residue 61 (Pro61) in loop 1 of ANT1 results in a
conformation that converts the ANT into a non-speciﬁc pore [128].
Non-conditional ANT1 null mice are viable and grow normally but
develop mitochondrial skeletal myopathy and cardiomyopathy [129].
Ablation both ANT isoforms inmouse liver surprisingly did not change
fundamentallymitochondrial permeability transition and cell death in
hepatocytes [132], and some ANT ligands induce mitochondrial
dysfunction and cytochrome c release independent of mitochondrial
permeability transition [133]. Thus, the mechanisms of ANT-induced
cell death are not understood fully.
CyPD (also named cyclophilin F, peptidyl prolyl iosmerase F) is
encoded by a single gene [114,116,134]. Despite confusing nomen-
clature, there is only one isoform of CyPD (EC 5.2.1.8, ppif gene
product) in mouse and human. The ~20 kDa protein encoded by this
gene is a member of the peptidyl-prolyl cis-trans isomerase (PPIase)
family. PPIases catalyze the cis-trans isomerization of proline imidic
peptide bonds in oligopeptides and accelerate the folding of proteins.
CyPD binds ANT1 [129].
During normal mitochondrial function the OMM and the IMM are
separated by the intermembrane space, and the VDAC and the ANT donot interact [114]. Permeability transition is activated by the for-
mation of the mPTP; the IMM looses its integrity and the ANT changes
its conformation from its native state into a non-selective pore [135].
This process is catalyzed by CyPD that functions in protein cis-trans
isomerization and chaperoning [136]. The ANT and CyPD interact
directly [137]. The molar concentration of CyPD (in heart mitochon-
dria) is much less (N5%) than ANT; thus, under normal conditions only
a minor fraction of the ANT can be in a complex with CyPD [117,138].
When this occurs, small ions and metabolites permeate freely across
the IMM and oxidation of metabolites by O2 proceeds with electron
ﬂux not coupled to proton pumping, resulting in collapse of ΔP,
dissipation of ATP production, production of ROS, equilibration of ions
between the matrix and cytosol, matrix volume increases, and mito-
chondrial swelling [115,119].
5.2. Expression and localization of mPTP components in the CNS
Very few studies have been published on the localizations of mPTP
components in the mammalian CNS; thus, details about the cellular
expressions in different nervous system cell types are lacking. VDAC
expression patterns are complicated by alternative splicing that
generates two different VDAC1 mRNAs, three different VDAC2
mRNAs, and two different VDAC3 mRNAs [118]. Studies of nervous
tissue have found VDAC in neurons and glial cells [139] and associated
with mitochondria, the endoplasmic reticulum, and the plasma mem-
brane [140,141]. Non-mitochondrial localizations of VDAC have been
disputed [142]. Information on ANT localizations in nervous tissue is
particularly scarce. ANT appears to be expressed in reactive astrocytes
[143]. The few existing studies on CyPD localization in mammalian
CNS have found it enriched in subsets of neurons in adult rat brain,
with some interneurons being positive [144], and relative low levels
in astrocytes [145,146].
In mouse spinal cord, the core components of the mPTP (VDAC,
ANT, and CyPD) are enriched in MNs as determined by immunohis-
tochemistry [78]. The speciﬁc isoforms of ANT and VDAC in MNs have
not been determined. CyPD, ANT, and VDAC have mitochondrial and
non-mitochondrial localizations in MNs [78]. They are all nuclear-
encoded mitochondrial-targeted proteins, thus a possible explanation
for their non-mitochondrial localizations is that they are pre-
mitochondrial forms. Some cyclophilins are located in the cytoplasm
[146], but CyPD immunoreactivity is annulled in ppif-/- mice,
demonstrating that the antibody is detecting only CyPD [78]. Spinal
cord, brainstem, and forebrain had similar levels of CyPD, as well as
similar levels of ANT and VDAC [78]. Thus, differences in the levels of
individual mPTP components cannot explain the intrinsic differences
in the sensitivity to Ca2+-induced permeability transition seen in
spinal cord and brain isolated mitochondria [147,148]. Not all
mitochondria within individual MNs contained CyPD, ANT, and
VDAC [78]; this observation supports that idea of that mitochondria
in individual cells are not only heterogeneous in shape [149,150] but
also in biochemical composition, notably metabolism [151] and
genetics [36].
5.3. The mPTP contributes to the pathogenesis of mouse ALS
The mPTP was ﬁrst implicated in ALS pathogenesis using pharma-
cological approaches. Cyclopsorine A treatment of G93Ahigh mice,
delivered intracerebroventricularly or systemically to mice on a
multiple drug resistance type 1a/b background, modestly improved
outcome [152–154], but these studies are confounded by the
immunosuppressant actions of cyclopsorine A through calcineurin
inhibition. Pharmacological studies using CyPD inhibitors devoid of
effects on calcineurin need to be done on ALS mice. Another study
showed that treatmentwith cholest-4-en-3-one oxime (TRO19622), a
drug that binds VDAC and the 18 kDa translocator protein (TSPO, or
peripheral benzodiazepine receptor), improved motor performance,
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However, another study using a different TSPO ligand (Ro-4864) did
not show positive effects with G93Ahigh mice [156].
CyPD and ANT have been identiﬁed as targets of nitration in ALS
mice [78]. CyPD nitration is elevated in early- to mid-symptomatic
stages, but declines to baseline at end-stage disease [78]. ANT nitration
is notable particularly because it is found in pre-symptomatic and
symptomatic stages but not at end-stage disease or in transgenic mice
expressing human wild-type SOD1 [78]. The ANT is important in the
context of age-related neurodegenerative disease because it under-
goes carbonyl modiﬁcation during aging in houseﬂy ﬂight muscle
[157] and rat brain [158]. In vitro cell-free and cell experiments have
shown that NO and ONOO- can act directly on the ANT to induce
mitochondrial permeabilization in a cyclosporine A-sensitive manner
[159]. Oxidative stress enhances the binding of CyPD to ANT [160].
Some SOD1 mutants are unstable and loose copper [67], and
interestingly, copper interactions with ANT and thiol modiﬁcation of
ANT can cause mPTP opening [161–163]. Together these data and
future work could reveal that oxidative and nitrative damage to
proteins, some of which are core components of themPTP, in G93Ahigh
mice is targeted rather than stochastic and could impinge on the
functioning of the mPTP.
The role of CyPD in the process of MN disease has been examined
in ALS mice through gene-ablation [78]. G93Ahigh-mSOD1 mice
without CyPD showmarkedly delayed disease onset and lived signiﬁ-
cantly longer than transgenic mice with CyPD. The effect of CyPD
deletion was much more prominent in females than in males [78].
Female mice even showed positive effects with haplo-deletion of
CyPD. Ppif gene ablation in transgenic mice with much lower levels
of human mSOD1 expression and a slower disease progression
(G93Alow-mSOD1 mice) also show signiﬁcantly delayed disease
onset and lived signiﬁcantly longer than transgenic mice with CyPD
[78]. Thus, some form of mitochondrial pathobiology is occurring
regardless of whether transgene expression of G93A is high or low.
Nevertheless, G93A-mSOD1 mice without CyPD develop eventu-
allyMNdisease and die. Otherwork on CypD null mice has shown that
high concentrations of Ca2+ (2 mM) can still lead to mPTP activation
without CyPD and that cell deaths caused by Bid, Bax, DNA damage
and TNF-α are not affected [164]. The effects of CyPD deﬁciency on
MN cell mechanisms thus need to be examined in more detail, but the
cell death phenotype might be switched or converted to another form
with the attenuation of mitochondrial swelling. A switch in the cell
deathmorphology andmolecular mechanisms inMNs of mSOD1mice
without CyPD is an outcome consistent with the cell death continuum
concept [12].
6. Summary and outlook
ALS is the 3rd most common human neurodegenerative disease
with an adult onset [1,2]. It is a paralytic disease that destroys MNs
and skeletal muscle and cannot yet be cured or treated effectively;
thus contracting the disease is fatal [5]. Mitochondria have diverse
functions and properties and could be critically important for the
development of human ALS [7]. Structural and biochemical data from
studies of human ALS and cell/animal models of ALS suggest that
mitochondrial dysfunction is a trigger or propagator of neurodegen-
eration. Mitochondria in subsets of neurons and skeletal muscle cells
could be compromised in ALS, rendering these cells intrinsically
susceptible to cellular aging and stress. Novel mechanisms for
mitochondriopathy and MN degeneration in human and mouse ALS
could involve apoptosis, accumulation of intracellular Ca2+, abnormal
trafﬁcking of mitochondria with enhanced ROS toxic potential from
distal dendrites or terminals at the neuromuscular junction, distal
axonopathy and target deprivation, NOS trafﬁcking and localization to
MN mitochondria, and ONOO- damage [79]. The mPTP actively par-
ticipates in the mechanisms of MN death in ALS mice in a gender-dependent pattern. Thus, mPTP activation is a possible triggering
event for MN degeneration and MN selective vulnerability in ALS
could be related to amount, composition, and trafﬁcking of mito-
chondria in MNs and the association of MN terminals with skeletal
muscle cells. There is precedence for this logic in mouse models of
Alzheimer's disease [165], multiple sclerosis [166], and stroke [167].
Further study of mitochondria in neurons and skeletal myocytes can
deﬁne new mechanisms of disease in ALS and can lead to the
identiﬁcation of molecular mechanism-based therapies for treating
this fatal disease.
Acknowledgments
The author thanks all of the individuals in his lab, particularly Yan
Pan, Ann Price, and Barry Gertz for data generated on human ALS and
G93A-mSOD1 mice. This work was supported by grants from the U.S.
Public Health Service, NIH-NINDS (NS065895, NS052098) and NIH-
NIA (AG016282).
References
[1] L.P. Rowland, N.A. Shneider, Amyotrophic lateral sclerosis, N. Engl. J. Med. 344
(2001) 1688–1700.
[2] S. Sathasivam, P.G. Ince, P.J. Shaw, Apoptosis in amyotrophic lateral sclerosis: a
review of the evidence, Neuropathol. Appl. Neurobiol. 27 (2001) 257–274.
[3] B. Stephens, R.J. Guiloff, R. Navarrete, P. Newman, N. Nikhar, P. Lewis, Widespread
loss of neuronal populations in spinal ventral horn in sporadic motor neuron
disease. A morphometric study, J. Neurol. Sci. 244 (2006) 41–58.
[4] S.Maekawa, S. Al-Sarraj,M. Kibble, S. Landau, J. Parnavelas, D. Cotter, I. Everall, P.N.
Leigh, Cortical selective vulnerability in motor neurons disease: a morphometric
study, Brain 127 (2004) 1237–1251.
[5] M. Cozzolino, A. Ferri, M.T. Carri, Amyotrophic lateral sclerosis: from current
developments in the laboratory to clinical implications, Antioxid. Redox Signal.
10 (2008) 405–443.
[6] E. Kabashi, P.N. Valdmains, P. Dion, D. Spiegelman, B.J. McConkey, C. Vande Velde,
J.-P. Bouchard, L. Lacomblez, K. Pochigaeva, F. Salachas, P.-F. Pradat, W. Camu, V.
Meininger, N. Dupre, G.A. Rouleau, TARDBP mutations in individuals with sporadic
and familial amyotrophic lateral sclerosis, Nat. Genet. 40 (2008) 572–574.
[7] L.J. Martin, Mitochondriopathy in Parkinson disease and amyotrophic lateral
sclerosis, J. Neuropathol. Exp. Neurol. 65 (2006) 1103–1110.
[8] J.C. Schymick, K. Talbot, G.J. Traynor, Genetics of amyotrophic lateral sclerosis,
Hum. Mol. Genet. 16 (2007) R233–R242.
[9] S.T. Hou, J.P. MacManus, Molecular mechanisms of cerebral ischemia-induced
neuronal death, Int. Rev. Cytol. 211 (2002) 93–148.
[10] D.B. Zorov, N.K. Isave, E. Yu, L.D.Zorova Plotnikov, E.V. Stelmashook, A.K. Vasileva,
A.A. Arkhagelskaya, T.G. Khrjapenkova, The mitochondrion as Janus Bifrons,
Biochemistry (Moscow) 72 (2007) 1115–1126.
[11] D.G. Nicholls, Mitochondrial function and dysfunction in the cell: its relevance to
aging and aging-related disease, Int. J. Biochem. Cell Biol. 34 (2002) 1372–1381.
[12] L.J. Martin, N.A. Al-Abdulla, A.M. Brambrink, J.R. Kirsch, F.E. Sieber, C. Portera-
Cailliau, Neurodegeneration in excitotoxicity, global cerebral ischemia, and
target deprivation: a perspective on the contributions of apoptosis and necrosis,
Brain Res. Bull. 46 (1998) 281–309.
[13] F.J. Northington, E.M. Graham, L.J. Martin, Apoptosis in perinatal hypoxic-
ischemic brain injury: how important is it and should it be inhibited? Brain Res.
Rev. 50 (2005) 244–257.
[14] F.J. Northington, M.E. Zelaya, D.P. O'Riordan, K. Blomgren, D.L. Flock, H. Hagberg,
D.M. Ferriero, L.J. Martin, Failure to complete apoptosis following neonatal
hypoxia-ischemia manifests as “continuum” phenotype of cell death and occurs
with multiple manifestations of mitochondrial dysfunction in rodent forebrain,
Neuroscience 149 (2007) 822–833.
[15] S. Sasaki, M. Iwata, Ultrastructural changes of synapses of Betz cell in patients
with amyotrophic lateral sclerosis, Neurosci. Lett. 268 (1999) 29–32.
[16] F.M. Menzies, P.G. Ince, P.J. Shaw, Mitochondrial involvement in amyotrophic
lateral sclerosis, Neurochem. Int. 40 (2002) 543–551.
[17] G.P. Comi, A. Bordoni, S. Salani, et al., Cytochrome c oxidase subunit I microdeletion
in a paitent with motor neuron disease, Ann. Neurol. 43 (1998) 110–116.
[18] G.M. Borthwick, R.W. Taylo, T.J. Walls, et al., Motor neuron disease in a patient
with a mitochondrial tRNAIle mutation, Ann. Neurol. 59 (2006) 570–574.
[19] N.W. Soong, D.R. Hinton, G. Cortopassi, N. Arnheim, Mosaicism for a speciﬁc
somatic mitochondrial DNA mutation in adult human brain, Nat. Genet. 2 (1992)
318–323.
[20] M. Corral-Debrinski, T. Horton, M.T. Lott, et al., Mitochondrial DNA deletions in
human brain: regional variability and increase with advanced age, Nat. Genet. 2
(1992) 324–329.
[21] C. Mawrin, E. Kirches, G. Krause, et al., Single-cell analysis of mtDNA levels in
sporadic amyotrophic lateral sclerosis, NeuroReport 15 (2004) 939–943.
[22] S. Corti, C. Donadonu, D. Ronchi, A. Bordoni, F. Fortunato, D. Santoro, R. Del Bo, V.
Lucchini, V. Crugnola, D. Papadimitriou, S. Salani, M. Moggio, N. Bresolin, G.P.
195L.J. Martin / Biochimica et Biophysica Acta 1802 (2010) 186–197Comi, Amyotrophic lateral sclerosis linked to a novel SOD1mutation with muscle
mitochondrial dysfunction, J. Neurol. Sci. 276 (2009) 170–174.
[23] D. Babcock, B. Hille, Mitochondrial oversight of cellular Ca2+ signaling, Curr.
Opin. Neurobiol. 8 (1998) 398–404.
[24] L. Siklos, J. Engelhardt, Y. Harat, et al., Ultrastructural evidence for altered calcium
in motor nerve terminals in amyotrophic lateral sclerosis, Ann. Neurol. 39 (1996)
203–216.
[25] M. Zoratti, I. Szabo, The mitochondrial permeability transition, Biochem. Biophys.
Acta 1241 (1995) 139–176.
[26] J.W. Olney, Brain lesion, obesity, and other disturbances in mice treated with
monosodium glutamate, Science 164 (1969) 366–368.
[27] D.W. Choi, Cellular defences destroyed, Nature 433 (2005) 696–698.
[28] M.R. Brown, P.G. Sullivan, J.W. Geddes, Synaptic mitochondria are more
susceptible to Ca2+ overload than nonsynaptic mitochondria, J. Biol. Chem. 281
(2006) 11658–11668.
[29] J.D. Rothstein, L.J. Martin, R.W. Kuncl, Decreased glutamate transport by brain
and spinal cord in amyotrophic lateral sclerosis, N. Engl. J. Med. 326 (1992)
1464–1468.
[30] J.D. Rothstein, M. Van Kammen, A.I. Levey, L.J. Martin, R.W. Kuncl, Selective loss of
glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis, Ann. Neurol.
38 (1995) (1995) 73–84.
[31] P.R. Heath, J. Tomkins, P.G. Ince, P.J. Shaw, Quantitative assessment of AMPA
receptor mRNA in human spinal motor neurons isolated by laser capture
microdissection, NeuroReport 13 (2002) 1753–1757.
[32] S. Kwak, Y. Kawahara, Deﬁcient RNA editing of GluR2 and neuronal death in
amyotrophic lateral sclerosis, J. Mol. Med. 83 (2005) 110–120.
[33] D.T.W. Chang, I.J. Reynolds, Mitochondrial trafﬁcking and morphology in healthy
and injured neurons, Prog. Brain Res. 80 (2006) 241–268.
[34] M.J. Hansson, R. Mansson, S. Morota, H. Uchino, T. Kallur, T. Sumi, N. Ishii, M.
Shimazu, M.F. Keep, A. Jegorov, E. Elmer, Calcium-induced generation of reactive
oxygen species in brain mitochondria is mediated by permeability transition,
Free Radic. Biol. Med. 45 (2008) 284–294.
[35] F. Bergmann, B.U. Keller, Impact of mitochondrial inhibition on excitability and
cytosolic Ca2+ levels in brainstem motoneurones, J. Physiol. 555 (2004) 45–59.
[36] D.C. Wallace, A mitochondrial paradigm of metabolic and degenerative diseases,
aging, and cancer: a dawn of evolutionary medicine, Annu. Rev. Genet. 39 (2005)
359–407.
[37] I. Fridovich, Superoxide radical and superoxide dismutases, Annu. Rev. Biochem.
64 (1995) 97–112.
[38] B. Halliwell, Role of free radicals in the neurodegenerative diseases, Drugs Aging
18 (2001) 685–716.
[39] J.S. Beckman, M. Carson, C.D. Smith, W.H. Koppenol, ALS, SOD and peroxynitrite,
Nature 364 (1993) 548.
[40] L.J. Martin, Z. Liu, DNA damage proﬁling in motor neurons: a single-cell analysis
by comet assay, Neurochem. Res. 27 (2002) 1089–1100.
[41] C. Giulini, Characterization and function of mitochondrial nitric-oxide synthase,
Free Radic. Biol. Med. 34 (2003) 397–408.
[42] G.C. Brown, V. Borutaite, Nitric oxide, cytochrome c and mitochondria, Biochem.
Soc. Symp. 66 (1999) 17–25.
[43] M.F. Beal, Oxidatively modiﬁed protein in aging and disease, Free Radic. Biol.
Med. 32 (2002) 797–803.
[44] R.J. Ferrante, S.E. Browne, L.A. Shinobu, A.C. Bowling,M.J. Baik, U.MacGarvey, N.W.
Kowall, R.H. Brown Jr., M.F. Beal, Evidence of increased oxidative damage in both
sporadic and familial amyotrophic lateral sclerosis, J. Neurochem. 69 (1997)
2064–2074.
[45] K. Abe, L.-H. Pan, M.Watanabe, T. Kato, Y. Itoyama, Induction of nitrotyrosine-like
immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis,
Neurosci. Lett. 199 (1995) 152–154.
[46] M.F. Beal, R.J. Ferrante, S.E. Browne, R.T. Matthews, N.W. Kowall, R.H. Brown Jr.,
Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral
sclerosis, Ann. Neurol. 42 (1997) 644–654.
[47] S. Sasaki, N. Shibata, T. Komori, M. Iwata, iNOS and nitrotyrosine immunoreac-
tivity in amyotrophic lateral sclerosis, Neurosci. Lett. 291 (2000) 44–48.
[48] S.E. Browne, A.C. Bowling, M.J. Baik, et al., Metabolic dysfunction in familial, but
not sporadic, amyotrophic lateral sclerosis, J. Neurochem. 71 (1998) 281–287.
[49] G.M. Borthwick, M.A. Johnson, P.G. Ince, P.J. Shaw, D.M. Turnbul, Mitochondrial
enzyme activity in amyotrophic lateral sclerosis: implications for the role of
mitochondria in neuronal cell death, Ann. Neurol. 46 (1999) 787–790.
[50] S. Vielhaber, D. Kunz, K. Winkler, et al., Mitochondrial DNA abnormalities in
skeletal muscle of patients with sporadic amyotrophic lateral sclerosis, Brain 123
(2000) 1339–1348.
[51] G. Soraru, L. Vergani, L. Fedrizzi, C. D'Ascenzo, A. Polo, B. Bernazzi, C. Angelini,
Activities of mitochondrial complexes correlate with nNOS amount in muscle
from ALS patients, Neuropathol. Appl. Neurobiol. 33 (2007) 204–211.
[52] A. Echaniz-Laguna, J. Zoll, E. Ponsot, B. N'Guessan, C. Tranchant, J.-P. Loefﬂer, E.
Lampert, Muscular mitochondrial function in amyotrophic lateral sclerosis is
progressively altered as the disease develops; a temporal study in man, Exp.
Neurol. 198 (2006) 25–30.
[53] S. Vielhaber, K. Winklwer, E. Kirches, D. Kunz, M. Buchner, H. Feistner, C.E. Elger,
A.C. Ludolph, M.W. Riepe, W.S. Kunz, Visualization of defective mitochondrial
function in skeletal muscle ﬁbers of patients with sporadic amyotrophic lateral
sclerosis, J. Neurol. Sci. 169 (1999) 133–139.
[54] J.C. Ameisen, On the origin, evolution, and nature of programmed cell death: a
timeline of four billion years, Cell Death Diff. 9 (2002) 367–393.
[55] D.E. Merry, S.J. Korsmeyer, Bcl-2 gene family in the nervous system, Annu. Rev.
Neurosci. 20 (1997) 245–267.[56] S. Cory, J.M. Adams, The bcl-2 family: regulators of the cellular life-or-death
switch, Nat. Rev. 2 (2002) 647–656.
[57] H.K. Lorenzo, S.A. Susin, Mitochondrial effectors in caspase-independent cell
death, FEBS Lett. 557 (2004) 14–20.
[58] H.Y. Cohen, S. Lavu, K.J. Bitterman, B. Hekking, T.A. Omahiyerobo, C. Miller, R.
Frye, H. Ploegh, B.M. Kessler, D.A. Sinclair, Acetylation of the C terminus of
Ku70 by CBP and PCAF controls Bax-mediated apoptosis, Mol. Cell 13 (2004)
627–638.
[59] L.J. Martin, Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible
contribution of a programmed cell deathmechanism, J. Neuropathol. Exp. Neurol.
58 (1999) 459–471.
[60] L.J. Martin, Z. Liu, Opportunities for neuroprotection in ALS using cell dealth
mechanism rationales, Drug Discov. Today 1 (2004) 135–143.
[61] L.J. Martin, Neuronal cell death in nervous system development, disease, and
injury, Int. J. Mol. Med. 4 (2001) 455–478.
[62] S.D. Ginsberg, S.E. Hemby, E.J. Mufson, L.J. Martin, Cell and tissue microdissection
in combination with genomic and proteomic proﬁling, in: L. Zaborszky, F.G.
Wouterlood, J.L. Lanciego (Eds.), Neuroanatomical Tract-Tracing 3. Molecules,
Neurons, and Systems, Springer, New York, 2006, pp. 109–141.
[63] L.J. Martin, Z. Liu, J. Pipino, B. Chestnut, M.A. Landek, Molecular regulation of DNA
damage-induced apoptosis in neurons of cerebral cortex, Cereb. Cortex 19
(2009) 1273–1293.
[64] J.E. Chipuk, T. Kuwana, L. Bouchier-Hayes, et al., Direct activation of Bax by p53
mediates mitochondrial membrane permeabilization and apoptosis, Science 303
(2004) 1010–1014.
[65] L.J. Martin, p53 is abnormally elevated and active in the CNS of patients with
amyotrophic lateral sclerosis, Neurobiol. Dis. 7 (2000) 613–622.
[66] L.J. Martin, Z. Liu, Injury-induced spinal motor neuron apoptosis is preceded by
DNA single-strand breaks and is p53- and Bax-dependent, J. Neurobiol. 50 (2002)
181–197.
[67] C. Bendotti, M.T. Carrì, Lessons from models of SOD1-linked familial ALS, Trends
Mol. Med. 10 (2004) 393–400.
[68] B.J. Turner, K. Talbot, Transgenics, toxicity and therapeutics in rodent models of
mutant SOD1-mediated familial ALS, Prog. Neurobiol. 85 (2008) 94–134.
[69] J.M. McCord, I. Fridovich, Superoxide dismutase, an enzymic function for
erythrocuprein (hemocuprein), J. Biol. Chem. 244 (1969) 6049–6055.
[70] R. Rakhit, J.P. Crow, J.R. Lepock, L.H. Kondejewski, N.R. Cashman, A. Chakrabartty,
Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate
in the oxidation models of sporadic and familial amyotrophic sclerosis, J. Biol.
Chem. 279 (2004) 15499–15504.
[71] A. Ferri, M. Cozzolino, C. Crosio, M. Nencini, A. Casciati, E.B. Gralla, G. Rotilio, J.S.
Valentine, M.T. Carri, Familial ALS-superoxide dismutases associate with mito-
chondria and shift their redox potentials, Proc. Natl. Sci. USA 103 (2006) (2006)
13860–13865.
[72] A.G. Estévez, J.P. Crow, J.B. Sampson,C. Reiter, Y. Zhuang,G.J. Richardson,M.M. Tarpey,
L. Barbeito, J.S. Beckman, Induction of nitric oxide-dependent apoptosis in motor
neurons by zinc-deﬁcient superoxide dismutase, Science 286 (1999) 2498–2500.
[73] S.W. Flanagan, R.D. Anderson, M.A. Ross, L.W. Oberley, Overexpression of
manganese superoxide dismutase attenuates neuronal death in human cells
expressing mutant (G37R) Cu/Zn-superoxide dismutase, J. Neurochem. 81
(2002) 170–177.
[74] M. Rizzardini, A. Mangolini, M. Lupi, P. Ubezio, C. Bendotti, L. Cantoni, Low levels
of ALS-linked Cu/Zn superoxide dismutase increase the production of reactive
oxygen species and cause mitochondrial damage and death in motor neuron-like
cells, J. Neurol. Sci. 323 (2005) 95–103.
[75] L.G. Bilsland, N. Nirmalananthan, J. Yip, L. Greensmith, M.R. Duhcen, Expression of
mutant SOD1G93A in astrocytes induces functional deﬁcits in motoneuron
mitochondria, J. Neurochem. 107 (2008) 1271–1283.
[76] M.E. Gurney, H. Pu, A.Y. Chiu, M.C. Dal Canto, C.Y. Polchow, D.D. Alexander, J.
Caliendo, A. Hentati, Y.W. Kwon, H.X. Deng, W. Chen, P. Zhai, R.L. Suﬁt, T.
Siddique, Motor neuron degeneration in mice that express a human Cu, Zn
superoxide dismutase mutation, Science 264 (1994) 1772–1775.
[77] M.C. Dal Canto, M.E. Gurney, Development of central nervous system pathology
in a murine transgenic model of human amyotrophic lateral sclerosis, Am. J.
Pathol. 145 (1994) 1271–1279.
[78] L.J. Martin, B. Gertz, Y. Pan, A.C. Price, J.D. Molkentin, Q. Chang, The mitochondrial
permeability transition pore in motor neurons: involvement in the pathobiology
of ALS mice, Exp. Neurol. 218 (2009) 333–346.
[79] L.J. Martin, Z. Liu, K. Chen, A.C. Price, Y. Pan, J.A. Swaby, W.C. Golden, Motor
neuron degeneration in amyotrophoc lateral sclerosis mutant superoxide
dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell
death, J. Comp. Neurol. 500 (2007) (2007) 20–46.
[80] Q. Chang, L.J. Martin, Glycinergic Innervation of motoneurons is deﬁcient in
amyotrophic lateral sclerosis mice: a confocal quantitative analysis, Am. J. Pathol.
174 (2009) 574–585.
[81] C. Bendotti, N. Calvaresi, L. Chiveri, A. Prelle, M. Moggio, M. Braga, V. Silani, S. De
Biasi, Early vacuolization and mitochondrial damage in motor neurons of FALS
mice are not associated with apoptosis or with changes in cytochrome oxidase
histochemical reactivity, J. Neurol. Sci. 191 (2001) 25–33.
[82] P.C. Wong, C.A. Pardo, D.R. Borchelt, M.K. Lee, N.G. Copeland, N.A. Jenkins, S.S.
Sisodia, D.W. Cleveland, D.L. Price, An adverse property of a familial ALS-linked
SOD1 mutation causes motor neuron disease characterized by vacuolar degener-
ation of mitochondria, Neuron 14 (1995) 1105–1116.
[83] J. Kong, Z. Xu, Massive mitochondrial degeneration in motor neurons triggers the
onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1,
J. Neurosci. 18 (1998) (1998) 3241–3250.
196 L.J. Martin / Biochimica et Biophysica Acta 1802 (2010) 186–197[84] D. Jaarsma, F. Rognoni, W. van Duijn, H.W. Verspaget, E.D. Haasdijk, J.C. Holstege,
CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in
transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1mutations,
Acta Neuropathol. 102 (2001) 293–305.
[85] C.M.J. Higgins, C. Jung, H. Ding, Z. Xu, Mutant Cu, Zn Superoxide dismutase
that causes motoneuron degeneration is present in mitochondria in the CNS,
J. Neurosci. 22 (RC215) (2002) 1–6.
[86] C.M. Higgins, C. Jung, Z. Xu, ALS-associated mutant SOD1G93A causes
mitochondrial vacuolation by expansion of the intermembrane space and by
involvement of SOD1 aggregation and peroxisomes, BMC Neurosci. 4 (2003) 16.
[87] D. Jaarsma, Swelling and vacuolation ormitochondria in transgenic SOD1-ALSmice:
a consequence of supranormal SOD1 expression? Mitochondrion 6 (2006) 48–49.
[88] S. Sasaki, H. Warita, T. Murakami, K. Abe, M. Iwata, Ultrastructural study of
mitochondria in the spinal cord of transgenic mice with a G93A mutant SOD1
gene, Acta Neuropathol. 107 (2004) 461–474.
[89] H.-X. Deng, A. Hentati, J.A. Tainer, Z. Iqbal, A. Cayabyab,W.-Y. Hung, E.D. Getzoff, P.
Hu, B. Herzfeldt, R.P. Roos, C. Warner, G. Deng, E. Soriano, C. Smyth, H.E. Parge, A.
Ahmed, A.D. Roses, R.A. Hallewell, M.A. Pericak-Vance, T. Siddique, Amyotrophic
lateral sclerosis and structural defects in Cu, Zn superoxide dismutase, Science
261 (1993) 1047–1051.
[90] D.R. Borchelt, M.K. Lee, H.H. Slunt, M. Guarnieri, Z.-S. Xu, P.C.Wong, R.H. Brown Jr.,
D.L. Price, S.S. Sisodia, D.W. Cleveland, Superoxide dismutase 1 with mutations
linked to familial amyotrophic lateral sclerosis possesses signiﬁcant activity, Proc.
Natl. Acad. Sci. USA 91 (1994) 8292–8296.
[91] M.B. Yim, J.-H. Kang, H.-S. Yim, H.-S. Kwak, P.B. Chock, E.R. Stadtman, A gain-of-
function of an amyotrophic lateral sclerosis-associated Cu, Zn-superoxide
dismutase mutant: an enhancement of free radical formation due to a decrease
in Km for hydrogen peroxide, Proc. Natl. Acad. Sci. USA 93 (1996) 5709–5714.
[92] E. Kabashi, P.N. Valdmanis, P. Dion, G.A. Rouleau, Oxidized/misfolded superoxide
dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann. Neurol. 62
(2007) 553–559.
[93] S.A. Ezzi, M. Urushitani, J.-P. Julien, Wild-type superoxide dismutase acquires
binding and toxic properties of ALS-linked mutant forms through oxidation,
J. Neurochem. 102 (2007) 170–178.
[94] S.I. Liochev, I. Fridovich, Mutant Cu, Zn superoxide dismutases and familial
amyotrophic lateral sclerosis: evaluation of oxidative hypotheses, Free Radic.
Biol. Med. 34 (2003) 1383–1389.
[95] P. Pacher, J.S. Beckman, L. Liaudet, Nitric oxide and peroxynitrite in health and
disease, Physiol. Rev. 87 (2007) 315–424.
[96] P.K. Andrus, T.J. Fleck, M.E. Gurney, E.D. Hall, Protein oxidative damage in a
transgenic mouse medel of familial amyotrophic lateral sclerosis, J. Neurochem.
71 (1998) 2041–2048.
[97] H.F. Poon, K. Hensley, V. Thongboonkerd, M.L. Merchant, B.C. Lynn, W.M. Pierce,
J.B. Klein, V. Calabrese, D.A. Butterﬁeld, Redox proteomics analysis of oxidatively
modiﬁed proteins in G93A-SOD1 transgenic mice- a model of familial
amyotrophic lateral sclerosis, Free Radic. Biol. Med. 39 (2005) 435–462.
[98] A. Okado-Matsumoto, I. Fridovich, Subcellular distribution of superoxide (SOD)
in rat liver, J. Biol. Chem. 276 (2001) 38388–38393.
[99] J. Liu, C. Lillo, A. Jonsson, C. Vande Velde, C.W.Ward, T.M.Miller, J.R. Subramaniam,
J.D. Rothstein, S.Marklund, P.M. Anderson, T.M. Brannstrom, O. Gredal, P.C.Wong,
D.S. Williams, D.W. Cleveland, Toxicity of familial ALS-linked SOD1 mutants from
selective recruitment to spinal mitochondria, Neuron 43 (2004) 5–15.
[100] P. Pasinelli, M.E. Belford, N. Lennon, B.J. Bacskai, B.T. Hyman, D. Trotti, R.H. Brown
Jr., Amyotrophic lateral sclerosis-associated SOD1 mutant protein bind and
aggregate with Bcl-2 in spinal cord mitochondria, Neuron 43 (2004) 19–30.
[101] C. Vande Velde, T.M. Miller, N.R. Cashman, D.W. Cleveland, Selective association
of misfolded ALS-linkedmutant SOD1with the cytoplasmic face ofmitochondria,
Proc. Natl. Acad. Sci. USA 105 (2008) 4022–4027.
[102] G. Goldsteins, V. Keksa-Goldsteine, T. Ahtiniemi, M. Jaronen, E. Arens, K.
Akerman, R.H. Chan, J. Koistinaho, Deleterious role of superoxide dismutase in
the mitochondrial intermembrane space, J. Biol. Chem. 283 (2008) 8446–8452.
[103] C. Vijayverguya, M.F. Beal, J. Buck, G. Manfredi, Mutant superoxide dismutase 1
forms aggregates in the brain mitochondrial matrix of amyotrophic lateral
sclerosis mice, J. Neurosci. 25 (2005) 2463–2470.
[104] M. Mattiazzi, M. D'Aurelio, C.D. Gajewski, K. Martushova, M. Kiaei, M.F. Beal,
G. Manfredi, Mutated human SOD1 causes dysfunction of oxidative phos-
phorylation in mitochondria of transgenic mice, J. Biol. Chem. 277 (2002)
29626–29633.
[105] K.J. De Vos, A.L. Chapman, M.E. Tennant, C. Manser, E.L. Tudor, K.-F. Lau, J.
Browlees, S. Ackerley, P.J. Shaw, D.M. McLoughlin, C.E. Shaw, P.N. Leigh, C.C.J.
Miller, A.J. Grierson, Familial amyotrophic lateral sclerosis-linked SOD1 mutants
perturb fast axonal transport to reduce axonal mitochondrial content, Hum. Mol.
Genet. 16 (2007) 2720–2728.
[106] L.J. Martin, K. Chen, Z. Liu, Adult motor neuron apoptosis is mediated by nitric
oxide and Fas death receptor linked by DNA damage and p53 activation,
J. Neurosci. 25 (2005) 6449–6459.
[107] L. Siklos, J.I. Engelhardt, M.E. Alexianu, M.E. Gurney, T. Siddique, S.H. Appel,
Intracellular calcium parallels motoneuron degeneration in SOD-1 mutant mice,
J. Neuropath. Exp. Neurol. 57 (1998) 571–587.
[108] M.K. Jaiswal, B.U. Keller, Cu/Zn superoxide dismutase typical for familial
amyotrophic lateral sclerosis increases the vulnerability of mitochondria and
perturbs Ca2+ homeostasis in SOD1G93Amice, Mol. Pharmacol. 75 (2009) 478–489.
[109] M. Damiano, A.A. Starkov, S. Petri, K. Kipiani, M. Kiaei, M. Mattiazzi, M.F. Beal, G.
Manfredi, Neural mitochondrial Ca2+ capacity impairment precedes the onset
of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice,
J. Neurochem. 96 (2006) 1349–1361.[110] K.T. Nguyen, L.E. Garcia-Chacon, J.N. Barrett, E.F. Barrett, G. David, The ψm
depolarization that accompanies mitochondrial Ca2+ uptake is greater in mutant
SOD1 than in wild-type mouse motor terminals, Proc. Natl. Acad. Sci. USA 106
(2009) 2007–2011.
[111] S. Sasaki, H. Warita, K. Abe, M. Iwata, Inducible nitric oxide synthase (iNOS) and
nitrotyrosine immunoreactivity in the spinal cords of transgenic mice with
mutant SOD1 gene, J. Neuropathol. Exp. Neurol. 60 (2001) 839–846.
[112] W.S. Kunz, Different metabolic properties of mitochondrial oxidative phosphor-
ylation in different cell types- important implications for mitochondrial
cytopathies, Exp. Physiol. 88.1 (2003) 149–154.
[113] D.R. Hunter, R.A. Haworth, J.H. Southard, Relationship between conﬁguration,
function, and permeability in calcium-treated mitochondria, J. Biol. Chem. 251
(1976) 5069–5077.
[114] M. Crompton, The mitochondrial permeability transition pore and its role in cell
death, Biochem. J. 341 (1999) 233–249.
[115] M. van Gurp, N. Festjens, G. van Loo, et al., Mitochondrial intermembrane
proteins in cell death, Biochem. Biophys. Res. Commun. 304 (2003) 487–497.
[116] P. Bernardi, A. Krauskopf, E. Basso, V. Petronilli, E. Blalchy-Dyson, F. Di Lisa, M.A.
Forte, The mitochondrial permeability transition from in vitro artifact to disease
target, FEBS J. 273 (2006) 2077–2099.
[117] A.W.C. Leung, A.P. Halestrap, Recent progress in elucidating the molecular
mechanism of the mitochondrial permeability transition pore, Biochim. Biophys.
Acta 1777 (2008) 946–952.
[118] V. Shoshan-Barmatz, A. Israelson, D. Brdiczka, S.S. Sheu, The voltage-dependent
anion channel (VDAC): function in intracellular signalling, cell life and cell death,
Curr. Pharm. Des. 12 (2006) 2249–2270.
[119] T.K. Rostovtseva, W. Tan, M. Colombini, On the role of VDAC in apoptosis: fact
and ﬁction, J. Bioenerg. Biomembranes 37 (2005) 129–142.
[120] D.J. Granville, R.A. Gottlieb, The mitochondrial voltage-dependent anion channel
(VDAC) as a therapeutic target for initiating cell death, Curr. Med. Chem. 10 (2003)
1527–1533.
[121] M. Huizing, W. Ruitenbeek, L.P. van den Heuvel, V. Dolce, V. Iacobazzi, J.A.M.
Smeitink, F. Palmieri, J.M.F. Trijbels, Human mitochondrial transmembrane
metabolite carriers: tissue distribution and its implication for mitochondrial
disorders, J. Bioenerg. Biomembranes 30 (1998) 277–284.
[122] S. Wu, M.J. Sampson, W.K. Decker, W.J. Craigen, Each mammalian mitochondrial
outer membrane porin protein is dispensable: effects on cellular respiration,
Biochem. Biophys. Acta 1452 (1999) 68–78.
[123] K. Anﬂous, D.D. Armstrong, W.J. Craigen, Altered sensitivity for ADP and main-
tenance of creatine-stimulated respiration in oxidative striated muscles from
VDAC1-deﬁcient mice, J. Biol. Chem. 276 (2001) 1954–1960.
[124] M.J. Sampson, W.K. Decker, A.L. Beaudet, W. Ruitenbeek, D. Armstrong, M.J.
Hicks, et al., Immotile sperm an infertility in mice lacking mitochondrial voltage-
dependent anion channel type 3, J. Biol. Chem. 276 (2001) 39206–39212.
[125] E.H. Cheng, T.V. Sheiko, J.K. Fisher, W.J. Craigen, S.J. Korsemeyer, VDAC2 inhibits
Bak activation and mitochondrial apoptosis, Science 301 (2003) 513–517.
[126] D. Chandra, G. Choy, P.T. Daniel, D.G. Tang, Bax-dependent regulation of Bak by
voltage-dependent anion channel 2, J. Biol. Chem. 280 (2005) 19051–19061.
[127] C.P. Baines, R.A. Kaiser, T. Sheiko, W.J. Craigen, J.D. Molkentin, Voltage-dependent
anion channels are dispensable for mitochondrial-dependent cell death, Nat. Cell
Biol. 9 (2007) 550–555.
[128] A.P. Helestrap, C. Brenner, The adenine nucleotide translocase: a central
component of the mitochondrial permeability transition pore and key player
in cell death, Curr. Med. Chem. 10 (2003) 1507–1525.
[129] B.H. Graham, K.G.Waymire, B. Cottrell, I.A. Trounce, G.R.MacGregor, D.C.Wallace,
A mouse model for mitochondrial myopathy and cardiomyopathy resulting from
a deﬁciency in the heart/muscle isoform of the adenine nucleotide translocator,
Nat. Genet. 16 (1997) 226–234.
[130] G. Stepien, A. Torroni, A.B. Chung, J.A. Hodge, D.C. Wallace, Differential expres-
sion of adenine nucleotide transloactor isoforms in mammalian tissues and
during muscle cell differentiation, J. Biol. Chem. 267 (1992) 14592–14597.
[131] M.Y. VyssokikH, A. Katz, A. Rueck, C. Wuensch, A. Dorner, D.B. Zorov, D. Brdiczka,
Adenine nucleotide translocator isoforms 1 and 2 are differently distributed in
the mitochondrial inner membrane and have distinct afﬁnities to cyclophilin D,
Biochem. J. 358 (2001) 349–358.
[132] J.E. Kikoszka, K.G. Waymire, S.E. Levy, J.E. Sligh, J. Cai, D.P. Jones, G.R. MacGregor,
D, C, Wallace, The ADP/ATP translocator is not essential for the mitochondrial
permeability transition pore, Nature 427 (2004) 461–465.
[133] K. Machida, Y. Hayashi, H. Osada, A novel adenine nucleotide translocase
inhibitor, MT-21, induces cytochrome c release through a mitochondrial
permeability transition-independent mechanisms, J. Biol. Chem. 277 (2002)
31243–31248.
[134] C.P. Baines, R.A. Kaiser, N.H. Purcell, H.S. Blair, H. Osinska, M.A. Hambleton, E.W.
Brunskill, M.R. Sayen, R.A. Gottlieb, G.W. Dorn II, J. Robbins, J.D. Molkentin, Loss of
cyclophilin D reveals a critical role for mitochondrial permeability transition in
cell death, Nature 434 (2005) 658–662.
[135] M. Crompton, Mitochondria and aging: a role for the permeability transition?
Aging Cell 3 (2004) 3–6.
[136] P.C. Waldmeier, K. Zimmermann, T. Qian, M. Tintelnot-Blomley, J.J. Lemasters,
Cyclophilin D as a drug target, Curr. Med. Chem. 10 (2003) 1485–1506.
[137] K. Woodﬁeld, A. Rück, D. Brdiczka, A.P. Halestrap, Direct demonstration of
a speciﬁc interaction between cyclophilin-D and the adenine nucleotide
translocase conﬁrms their role in the mitochondrial permeability transition,
Biochem. J. 336 (1998) 287–290.
[138] N. Johnson, A. Khan, S. Virji, J.M. Ward, M. Crompton, Import and processing of
heart mitochondrial cyclophilin D, Eur. J. Biochem. 263 (1999) 353–359.
197L.J. Martin / Biochimica et Biophysica Acta 1802 (2010) 186–197[139] M.W. McEnery, T.M. Dawson, A. Verma, D. Gurley, M. Colombini, S.H. Snyder,
Mitochondrial voltage-dependent anion channel, J. Biol. Chem. 268 (1993)
23289–23296.
[140] V. Shoshan-Barmatz, R. Zalk, D. Gincel, N. Vardi, Subcellular localization of VDAC
in mitochondria and ER in the cerebellum, Biochem. Biophys. Acta 1657 (2004)
105–114.
[141] N. Akanda, R. Toﬁght, J. Brask, C. Tamm, F. Elinder, S. Ceccatelli, Voltage-
dependent anion channels (VDAC) in the plasmamembrane play a critical role in
apoptosis in differentiated hippocampal neurons but not in neural stem cells, Cell
Cycle 7 (2008) 3225–3234.
[142] W.H. Yu, W. Wolfgang, M. Forte, Subcellular localization of human voltage-
dependent anion channel isoforms, J. Biol. Chem. 270 (1995) 13998–14006.
[143] C.R. Buck, M.J. Jurynec, D.E. Upta, A.K.T. Law, J. Bilger, D.C. Wallace, R.J. McKeon,
Increased adenine nucleotide translocator 1 in reactive astrocytes facilitates
glutamate transport, Exp. Neurol. 181 (2003) 149–158.
[144] J.L. Hazelton, M. Petrasheuskaya, G. Fiskum, T. Kristian, Cyclophilin D is expressed
predominantly in mitochondria of γ-aminobutyric acidergic interneurons,
J. Neurosci. Res. 87 (2009) 1250–1259.
[145] K.K. Naga, P.G. Sullivan, J.W. Geddes, High cyclophilin D content of synaptic mito-
chondria results in increased vulnerability to permeability transition, J. Neurosci. 27
(2007) 7469–7475.
[146] S. Bose, R.B. Freedman, Peptidyl prolyl cis-trans-isomerase activity asso-
ciated with the lumen of the endoplasmic reticulum, Biochem. J. 300 (1994)
865–870.
[147] P.G. Sullivan, A.G. Rabchevsky, J.N. Keller, M. Lovell, A. Sodhi, R.P. Hart, S.W.
Scheff, Intrinsic differences in brain and spinal cord mitochondria: implications
for therapeutic interventions, J. Comp. Neurol. 474 (2004) 524–534.
[148] S. Morota, M.J. Hansson, N. Ishii, Y. Kudo, E. Elmer, H. Uchino, Spinal cord
mitochondria display lower retention capacity compared with brain mitocho-
chondria without inherent differences in sensitivity to cyclophilin D inhibition,
J. Neurochem. 103 (2007) 2066–2076.
[149] T.J. Collins, M.D. Bootman, Mitochondria are morphologically heterogeneous
within cells, J. Exp. Biol. 206 (2003) 1993–2000.
[150] R.E. Jensen, 2005, Control of mitochondrial shape, Curr. Opin. Cell Biol. 17 (2005)
384–388.
[151] A. Hamberger, C. Blomstrand, A.L. Lehninger, Comparative studies of mitochon-
dria isolated from neuron-enriched and glia-enriched fractions of rabbit and beef
brain, J. Cell Biol. 45 (1970) 221–234.
[152] M. Keep, E. Elmér, K.S.K. Fong, K. Csiszar, Intrathecal cyclosporin prolongs
survival of late-stage ALS mice, Brain Res. 894 (2001) 27–331.
[153] J. Karlsson, K.S. Fong, M.J. Hansson, E. Elmer, K. Csiszar, M.F. Keep, Life span
extension and reduced neuronal death after weekly intraventricular cyclospor-
ine injections in the G93A transgenic mouse model of amyotrophic lateral
sclerosis, J. Neurosurg. 101 (2004) 128–137.
[154] I.G. Kirkinezos, D. Hernandez, W.G. Bradley, C.T. Moraes, An ALS mouse model
with a permeable blood-brain barrier beneﬁts from systemic cyclosporine A
treatment, J. Neurochem. 88 (2004) 821–826.[155] T. Bordet, B. Buisson, M. Michaud, C. Drouot, P. Galea, P. Delaage, N.P. Akentieva,
A.S. Evers, D.F. Covey, M.A. Ostuni, J.J.-J. Lacapere, C. Massaad, M. Schmacher,
E.-M. Steidl, D. Maux, M. Delaage, C.E. Henderson, R.M. Pruss, Identiﬁcation and
characterization of Cholest-4-en-3-one, oxime (TRO19622), a novel drug
candidate for amyotrophic lateral sclerosis, J. Pharmacol. Exp. Ther. 322 (2007)
709–720.
[156] C. Mills, M.Makwana, A.Wallace, S. Benn, H. Schmidt, I. Tegeder, M. Costigan, R.H.
Brown Jr., G. Raivich, C. Woolf, Ro5–4864 promotes neonatal motor neuron
survival and nerve regeneration in adult rats, Eur. J. Neurosci. 27 (2008) 937–946.
[157] L.-J. Yan, R.S. Sohal, Mitochondrial adenine nucleotide translocase is modiﬁed
oxidatively during aging, Proc. Natl. Acad. Sci. USA 95 (1998) 12896–12901.
[158] L. Prokai, L.-J. Yan, J.L. Vera-Serrano, S.M. Stevens Jr., M.J. Forster, Mass
spectrometry-based survey of age-associated protein carbonylation in rat brain
mitochondria, J. Mass Spectrom. 42 (2007) 1583–1589.
[159] H.L.A. Vieira, A.-S. Belzacq, D. Haouzu, F. Bernassola, I. Cohen, E. Jacotot, K.F. Ferri,
C.E. Hamel, L.M. Bartle, G. Melino, C. Brenner, V. Goldmacher, G. Kroemer,
The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and
4-hydroxynonenal, Oncogene 20 (2001) 4305–4316.
[160] G.P. McStay, S.J. Clarke, A.P. Halestrap, Role of critical thiol groups on the matrix
surface of the adenine nucleotide translocase in the mechanism of the
mitochondrial permeability transition pore, Biochem. J. 367 (2002) 541–548.
[161] P. Costantini, R. Colonna, P. Bernardi, Induction of themitochondrial permeability
transition by N-ethylmaleimide depends on secondary oxidation of critical thiol
groups. Potentiation by copper-ortho-phenthroline without dimerization of the
adenine nucleotide translocase, Biochim. Biophys. Acta 1365 (1998) 385–392.
[162] P. Costantini, A.-S. Belzacq, H.L.A. Vieira, N. Larochette, M.A. de Pablo, N.
Zamzami, S.A. Susin, C. Brenner, G. Kroemer, Oxidation of a critical thiol residue
of the adenine nucleotide translocator enforces Bcl-2-independent permeability
transition pore opening and apoptosis, Oncogene 19 (2000) 307–314.
[163] N. García, E. Martínez-Abundis, N. Pavón, F. Correa, E. Chávez, Copper induces
permeability transition through its interaction with the adenine nucleotide
translocase, Cell Biol. Int. 31 (2007) 893–899.
[164] S. Grimm, D. Brdiczka, The permeability transition pore in cell death, Apoptosis
12 (2007) 841–855.
[165] H. Du, L. Guo, F. Fang, D. Chen, A.A. Sosunov, G.M. McKhann, Y. Yan, C. Wang, H.
Zhang, J.D. Molkentin, F.J. Gunn-Moore, J.P. Vonsattel, O. Aranico, J.X. Chen, S.D.
Yan, Cyclophilin D deﬁciency attenuates mitochondrial and neuronal perturba-
tion and ameliorates learning and memory in Alzheimer's disease, Nat. Med. 14
(2008) 1097–1105.
[166] M. Forte, B.G. Gold, G. Marracci, P. Chaudhary, E. Basso, D. Johnsen, Z. Yu, J.
Fowlkes, M. Rahder, K. Stern, P. Bernardi, D. Bourdette, Cyclophilin D inactivation
protects axons in experimental autoimmune encephalomyelitis, an animalmodel
of multiple sclerosis, Proc. Natl. Acad. Sci. USA 104 (2007) (2007) 7558–7563.
[167] A.C. Schinzel, O. Takeuchi, Z. Huang, J.K. Fisher, Z. Zhou, J. Rubens, C. Hertz, N.N.
Danial, M.A. Moskowitz, S.J. Korsmeyer, Cyclophilin D is a component of mito-
chondrial permeability transition and mediates neuronal cell death after focal
cerebral ischemia, Proc. Natl. Acad. Sci. USA 102 (2005) 12005–12010.
